Evidence map›Paper›PMID 40002954›Full record

ReviewAnimals : an open access journal from MDPI2025

Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine.

Jianzhong Wang, Xueying Zhou, Sara T Elazab, Jian Huang, Walter H Hsu

Abstract readReview
In one paragraph

Review in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianzhong WangShanxi Key Laboratory for Modernization of TCVM, College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China.ORCID 0000-0002-3349-2318
Xueying ZhouDepartment of Veterinary Clinical Science, College of Veterinary Medicine, China Agricultural University, Beijing 100107, China.
Sara T ElazabDepartment of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-3348-7084
Jian HuangInstitute of Qinhai-Tibetan Plateau, College of Animal Husbandry and Veterinary Medicine, Southwest Minzu University, Chengdu 610041, China.
Walter H HsuDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.

Funding

Central Funds Guiding the Local Science and Technology Development in Shanxi Province YDZJSX2021A034
6 · The paper itself

Abstract

Monoclonal antibody therapy has been a cornerstone of human healthcare for nearly four decades, effectively treating a wide range of diseases including cancers, autoimmune disorders, and inflammatory conditions. However, its application in veterinary medicine is a relatively recent development, offering a promising therapeutic approach for managing chronic diseases in small animals. Dogs and cats, like humans, suffer from chronic conditions such as cancer, arthritis, allergies, and chronic pain, which mAb therapy could potentially address. This review aims to explore the therapeutic potential of mAb therapy in small animal medicine, focusing on currently authorized products, including their mechanisms of action, clinical efficacy, and safety concerns. A comprehensive review of the literature was conducted to evaluate the use of mAbs in veterinary medicine, specifically in the treatment of chronic disorders. While mAb therapy has shown significant benefits in human healthcare, challenges remain in its application to veterinary practice, including safety concerns and the limited availability of approved products. Despite these challenges, mAb therapy holds great promise for improving the management of chronic diseases in animals, with future research and development potentially expanding its clinical use.

Indexed as

atopic dermatitiscanine interleukin 31chronic disordersimmunotherapylymphomamAb therapymonoclonal antibodynerve growth factorosteoarthritispet animals

Identifiers

PMID40002954
PMCPMC11852019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.